AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Telomir Pharmaceuticals, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01K4SG4R3
0.98▼ 0.03 (-3.46%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
1.01
Day's Range
0.96 – 0.99
52-Week Range
0.89 – 1.58
Volume
46.9K
Avg Volume
118.7K
Share Statistics
Shares Outstanding
Employees
5
Exchange
XNAS
Listed
2024-02-09
Share count as of August 12, 2026

Telomir Pharmaceuticals, Inc. Common Stock (TELO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Telomir Pharmaceuticals, Inc. Common Stock (TELO)
What is Telomir Pharmaceuticals, Inc. Common Stock's Market Cap?
Telomir Pharmaceuticals, Inc. Common Stock's Market Cap is $67.1M, based on as-reported figures from SEC (XBRL) filings.
What is Telomir Pharmaceuticals, Inc. Common Stock's Revenue (TTM)?
Telomir Pharmaceuticals, Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Telomir Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
Telomir Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$5.9M, based on as-reported figures from SEC (XBRL) filings.
What is Telomir Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Telomir Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -0.09, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TELOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
Operating costs:
Selling, General and Administrative Expense
Research and Development Expense
Total operating costs
Interest and Dividend Income (Non-Bank)
Interest expense—
Total other income, net——
Net loss
Deemed dividend——
Net loss attributable to common stockholders——
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—